← All trials
NCT06425224
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2022
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- May 22, 2024
- Last posted
- May 22, 2024
- Enrollment
- 129
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boston Medical GroupLead sponsor
- Boston Medical GroupOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.